From the Journals

In and out surgeries become the norm during pandemic


 

Case studies in nephrectomy

While several case studies have looked at the feasibility and safety of performing partial and radical nephrectomy with same-day discharge in select cases, “this topic has not been addressed on a national level,” Mr. Garden said.

Few patients who have partial or radical nephrectomies have same-day discharges. The researchers found that fewer than 1% of patients who have either procedure in the sample studied were discharged the same day.

Researchers used the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database, a nationally representative deidentified database that prospectively tracks patient characteristics and 30-day perioperative outcomes for major inpatient and outpatient surgical procedures at more than 700 hospitals.

They extracted all minimally invasive partial and radical nephrectomies from 2012 to 2019 and refined the cohort to 28,140 patients who were theoretically eligible for same-day discharge: Of those, 237 (0.8%) had SSD, and 27,903 (99.2%) had a standard-length discharge (SLD).

The team found that there were no differences in 30-day complications or readmissions between same-day discharge (Clavien-Dindo [CD] I/II, 4.22%; CD III, 0%; CD IV, 1.27%; readmission, 4.64%); and SLD (CD I/II, 4.11%; CD III, 0.95%; CD IV, 0.79%; readmission, 3.90%; all P > .05).

Controlling for demographic and clinical variables, SDD was not associated with greater risk of 30-day complications or readmissions (CD I/II: odds ratio, 1.08; 95% confidence interval, 0.57-2.048; P = .813; CD IV: OR 1.699; 95% CI, 0.537-5.375; P = .367; readmission: OR, 1.254; 95% CI, 0.681-2.31; P = .467).

Mr. Garden and coauthors report no relevant financial relationships.

Dr. Lane reports no relevant financial relationships.

Pages

Recommended Reading

Novel trastuzumab duocarmazine significantly improved survival in advanced HER2-positive breast cancer
MDedge Hematology and Oncology
Many patients, doctors unaware of advancements in cancer care
MDedge Hematology and Oncology
MRI screening cost effective for women with dense breasts
MDedge Hematology and Oncology
New approval in early breast cancer: First advance in 20 years
MDedge Hematology and Oncology
No advantages to using ADM in implant-based breast reconstruction
MDedge Hematology and Oncology
Neuroimaging may predict cognitive decline after chemotherapy for breast cancer
MDedge Hematology and Oncology
Does eating nuts lead to better breast cancer outcomes?
MDedge Hematology and Oncology
Convenience, not outcomes may drive robot-assisted surgeries
MDedge Hematology and Oncology
Antibiotic and glucocorticoid use before cancer therapy could have detrimental effect on outcomes
MDedge Hematology and Oncology
FDA issues stronger safety requirements for breast implants
MDedge Hematology and Oncology